Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Increased to $18.00 by Analysts at JPMorgan Chase & Co.

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by JPMorgan Chase & Co. from $16.00 to $18.00 in a report published on Monday, Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

A number of other research analysts also recently commented on the stock. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group increased their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Argus upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. Finally, Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $19.33.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $18.18 on Monday. Teva Pharmaceutical Industries has a 12-month low of $8.06 and a 12-month high of $19.08. The company has a market capitalization of $20.60 billion, a price-to-earnings ratio of -46.61, a price-to-earnings-growth ratio of 1.29 and a beta of 0.88. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm’s fifty day moving average price is $17.99 and its 200 day moving average price is $16.68.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The firm had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.33 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $28,000. EntryPoint Capital LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter worth about $30,000. UMB Bank n.a. lifted its holdings in shares of Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $52,000. Finally, Beach Investment Counsel Inc. PA bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $48,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.